Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 7

NCT ID: NCT05048368 Not yet recruiting - Esophageal Cancer Clinical Trials

Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Start date: December 30, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

NCT ID: NCT04906473 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors

Start date: July 31, 2021
Phase: Phase 1
Study type: Interventional

to assess the safety,tolerability, pharmacokinetic,pharmacodynamics and efficacy of KY100001 in patients with advanced solid tumors

NCT ID: NCT04891653 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of BR790 in Subjects With Advanced Solid Tumors

Start date: June 30, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase II clinical trial dose (RP2D) .The study is divided into two phases: dose escalation phase and dose expansion phase.

NCT ID: NCT04871347 Not yet recruiting - Clinical trials for Advanced Solid Tumor

The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor

Start date: August 30, 2021
Phase: Phase 1
Study type: Interventional

This is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety and efficacy of TWP-101 in patients with advanced solid tumor. This study consists of two parts (Part A and Part B). Part A was a dose escalation study, and Part B was a dose expansion study.

NCT ID: NCT04675528 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Food Effect on Pharmacokinetics and SafEty of DHP107 (Liporaxel®) FEEL Study

FEEL
Start date: January 2021
Phase: Phase 1
Study type: Interventional

To evaluate the food effect on pharmacokinetics of DHP107 in patients with advanced solid tumors.

NCT ID: NCT04151186 Not yet recruiting - Neoplasms Clinical Trials

A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors

Start date: November 20, 2019
Phase: N/A
Study type: Interventional

- Transmembrane 4 L Six Family Member 1 (TM4SF1) and Epithelial cell adhesion molecule (EpCAM) are both highly expressed in many epithelial-derived solid tumors. - The Chimeric Antigen Receptor T-cells (CAR-T) that target TM4SF1 or EpCAM have been generated respectively in our good manufacturing practices (GMP) facility and their anti-tumor effects have been demonstrated in multiple in vitro and in vivo studies. - Clinical studies are proposed here to evaluate the anti-tumor activity of these cell therapy products for treatment of patients with TM4SF1 or EpCAM positive tumors. In this study, the safety, tolerance, and preliminary efficacy of CART-TM4SF1 and CART-EpCAM cells will be examined inpatients with refractory/recurrent advanced pancreatic cancer, colorectal cancer, gastric cancer or lung cancer. And 9 patients for each cancer will be evaluated. - Clinical and immunological responses will be evaluated about 30 days and last up to 2 years after CAR-T cell infusion.

NCT ID: NCT04049929 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors

Start date: August 2019
Phase: Phase 1
Study type: Interventional

Protocol YY-20394-003 is a phase I single arm, open label study. The primary objective is to assess the safety of YY-20394 in subjects with advanced solid tumor. The secondary objective is to determine the preliminary efficacy and pharmacokinetics (PK).

NCT ID: NCT03260179 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810

Start date: August 31, 2017
Phase: Phase 1
Study type: Interventional

This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and personalized medicine for the patients of high-incidence-rates cancer in China.